| CHINESE | JAPANESE | KOREAN |
  Home         Investment Guide          News          Special Coverage          News in Retrospect          Contact Us
  Industries & Enterprises  | Tourism & Leisure  | Education & Schools  | Infrastructure & Ecology  | Life & Culture  | Authorities & Policies
 
  The Scholarly SIP with...
书香园区 (3).png
 
  2017 China Suzhou Cult...
创博会专题-03.png
 
  Spring Outing at Yangc...
春行半岛-03.png
 
  SIP accelerates to sha...
人工智能专题-03.png
 
  Enjoy the Spring in SIP
QQ图片20170410131338.png
 
 
Current Position: Home page > News
  Print page Text size:  
 


Alphamab and 3DMed Join Hands in Developing New Anti-tumor Drug


On the morning of February 29, Alphamab Co. Ltd signed a cooperation agreement with 3DMed on the joint development of KN035 biological reagent of the new generation PD-L1 single domain anti-body.

It is reported that the new drug, PD-L1 single domain anti-body, to be developed by the two sides, will focus on the immunity against tumors.

"The new anti-tumor drug will be applied for hypodermic injection instead of the current traditional intravenous injection, and is therefore more safe and acceptable to the patient," said Gong Zhaolong, CEO of 3DMed. As a stable reagent, the anti-body of new type will reinforce the attack on tumors by the immunity cells of the human body with little toxic side effect. Application report is expected to be filed in the near future both in China and the US for clinical trial of the new drug. The cooperation between Alphamab and 3DMed will be completely on equal footing in matters of applying for clinical experiment, clinical study, market sales, and production. 


March 1, 2016

 
 
   
 
  FEATURED VIDEOS  
     
   
  Suzhou Industrial Park Video  
  Watch